OSE Immunotherapeutics (France)
company in Paris, France
ISIN FR0012127173 LEI 969500HIUWVGY6NZSM05
Follow OSE Immunotherapeutics (France)
Weekly email: filings, results
Revenue, last year
€2.6M
−96.3% vs prior year
Net income
−€37.7M
−200.7% vs prior year
EPS, diluted
−€1.69
−215.8% vs prior year
Operating cash flow
−€34M
−170.3% vs prior year
Source: ESEF annual reports · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | €2.6M | −€37.7M |
| FY24 | €69.9M | €37.4M |
| FY23 | €2.2M | −€23M |
| FY21 | €26.3M | −€16.9M |
| FY20 | €10.4M | −€16.6M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −1431.3% | −1439.1% |
| FY24 | 62.6% | 53.6% |
| FY23 | −1032.2% | −1032.9% |
| FY21 | −63.2% | −64.1% |
| FY20 | −182% | −158.7% |
- OSE Immunotherapeutics (France)
- Healthcare median
Show the numbers
| Year | OSE Immunotherapeutics (France) | Healthcare median |
|---|---|---|
| FY25 | −1439.1% | −30.6% |
| FY24 | 53.6% | −47% |
| FY23 | −1032.9% | −58% |
| FY21 | −64.1% | −71.9% |
| FY20 | −158.7% | −62.2% |